Immunotherapy

30 March -1 April 2020 | Business Design Centre London

 

 

2000+
Attendees
700+
1-2-1 Meetings
300+
Speakers
100+
Exhibitors
12
Streams

 

 

Innovation

INNOVATION, Tuesday 31 March 2020

CONFERENCE DAY 1 - TUESDAY 31st March 2020

Opening Keynotes Day 1 – CAR-T & Immunotherapy focus

08:45

Welcome – Jessica Robinson, Project Director, Advanced Therapies 2020, Terrapinn

Prasad Adusumilli
09:00

Keynote presentaton: Autologous Mesothelin-targeting CAR-T to tackle solid tumours in the clinic

  • The presentation will highlight results to date of mesothelin-targeted CAR T-cell clinical trial results
  • Advances in preclinical research of CAR T-cell therapy for solid tumors will be presented
  • Novel strategies for overcoming hurdles to solid tumor CAR T-cell therapy will be discussed
Panel discussion
Bradley Campbell
10:00

Importance of patient focus in developing gene therapy for rare diseases

10:20

Morning Coffee Break

Martin Pule
11:20

Keynote presentation: War in the Blood - the latest in the front line of CAR-T clinical research

Mark Sawicki
11:40

Effective Integration Strategies Through a Compliance Unified Ecosystem (CUE)

  • Systems Integration continues to be a major issue in the production and distribution of Advanced Therapies
  • Well-defined strategies for the integration of independent informatics platforms will be critical for future standardization and workflow optimization
  • Cryoport’s Compliance Unified Ecosystem (CUE) is driving standard practices for systems integration in the industry
round tables
12:00

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for you

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for your table number to participate.
1. Raw material supply for the commercial manufacturing of cell and gene therapies
Frank Hecht

Frank Hecht, Vice President Marketing And Sales, CellGenix GmbH

10. Exploring the crossover between human and veterinary applications for stem cells
Joanna Miller

Joanna Miller, Chief Scientific Officer, Cell Therapy Sciences

15. Industry-no profit alliances: how to optimize synergies
Elena Beltrami

Elena Beltrami, Business Development Manager, Fondazione Telethon

16. Industrialisation of ATMPs
Mark Lowdell

Mark Lowdell, Chief Scientific Officer, Inmunebio

17. How companies can interact with the regulator and various pitfalls to be aware of
John Johnston

John Johnston, Clinical Assessor, Medicines & Healthcare Products Regulatory Agency

19. Roundtable available
2. Physiological conditions and analytical and monitoring tools for 3D cell cultivations
Cornelia Kasper

Cornelia Kasper, Professor, Biopharmaceutical Production And Technology, BOKU

21. Neurological applications for ATMPs
John Isaac

John Isaac, Senior Director, External Scientific Innovation And Neuroscience, Johnson & Johnson

22. Development of regenerative medicines for cardiovascular indications
David Mazzo

David Mazzo, Chief Executive Officer, Caladrius Biosciences

3. Ensuring safe delivery to patients and fast time-to-market of advanced therapies - How to address challenges of drug administration, fill & finish, packaging & stability?
Diana Lober

Diana Lober, Product Manager, Schott AG

5. Considerations for manufacture scale-up from academia to commercial manufacturing
Johannes Van Der Loo

Johannes Van Der Loo, Clinical Vector Core Director, The Children's Hospital of Philadelphia

7. Reserved for Fujifilm Diosynth Biotechnology
13:00

Lunch

INNOVATION

Special Session: RNA Targeted Therapeutics

Yochi Slonim
INNOVATION
14:20

Translation Control Therapeutics: discovery of small molecule drugs that control mRNA translation into proteins

  • The novel target space of mRNA translation regulation
  • Discovery of small molecule drugs that selectively control mRNA translation
  • Anima Biotech:bi-directional and tissue selective translation controlling drugs
Evelina Vågesjo
INNOVATION
15:00

Taking a novel next- generation biologic from idea to clinical proof of concept

Vittorio Colizzi
INNOVATION
15:20

Plant Micro-vesicles containing smallRNAs in delivering and adjuvancy for sustainably cancer therapy

16:20

Afternoon Break

Elena Costariol
INNOVATION
17:00

Process Development and Manufacture of CAR- T cells in an automated, stirred- tank bioreactor

Nina Bauer
INNOVATION
17:20

Cost effective manufacturing strategies – thinking outside the box

Julian Gough
INNOVATION
17:40

Using big data applications to transform any cell type

  • Network-based algorithms to find transcription factors that lead to a change is cell state
  • Generating cell conversion protocols
  • Characterise and understand the cell type using microscopic and genetic markers
18:00

Close of Conference for the day - Please join us for an evening drinks reception

last published: 04/Jun/20 09:25

INNOVATION, Wednesday 1 April 2020

CONFERENCE DAY 1 - WEDNESDAY 1st April 2020

Opening Keynotes Day 2 — The latest science in gene therapy and gene editing

Federico Mingozzi
09:00

Gene therapy 2.0: New clinical data, therapeutic applications and next generation technologies

  • Latest updates on LUXTURNA studies to treat blindness, haemophilia and rare disease
  • Tackling the challenges of viral gene therapies i.e. immunogenicity
  • Developing the next generation of gene therapies, what does the future hold?
Steve Kanner
09:20

Next-generation gene editing technology for allogeneic immune cell therapeutics

  • Next-generation CRISPR-Cas9 technology
  • Significantly enhanced editing specificity
  • Editing in immune cells for generation of functionally tuned therapeutics
Amy Pooler, Director, Neuroscience, Sangamo Theraputics
09:40

Repairing the human genome with designed zinc finger editing reagents

  • Overview of Sangamo’s zinc finger protein gene editing technology, including new innovations that facilitate specificity, precision, and gene editing efficiency
  • Will address specific examples of defined therapeutic applications including the generation of reagents suitable for use in tauopathies, Huntington’s disease, and lysosomal storage diseases
Frederic Chereau
10:00

In vivo gene editing paediatric patients with rare diseases

10:20

Networking Refreshments

INNOVATION

Exosome Therapeutics

Dr Bo Kara
INNOVATION
11:20

Engineered Exosome Therapeutics – Development and Manufacturing

Dr Bo Kara, Vice President Process Development, Evox Therapeutics
Randolph Corteling
INNOVATION
11:40

An Exosome-based Drug Delivery Platform Derived from a Human Neural Stem Cell (hNSC) Line

  • To ensure the scale required for clinical research and commercialisation producer cell immortalisation and clonal isolation is a practical strategy to produce consistent, functionally bioactive exosomes for use as therapeutic agents.
  • The cell line can be rapidly modified to alter exosome cargo or reprogrammed to change its phenotype while maintaining its conditional immortalisation.
  • hNSC derived exosomes demonstrate favourable distribution across the blood brain barrier.
Aisha Khan
INNOVATION
12:20

Development and GMP Compliant Manufacturing of Mesenchymal Stem Cell (MSC) Derived Exosomes for Regenerative

Aisha Khan, Executive Director Of Lab Operations At The Interdisciplinary Stem Cell Institute, Miller School of Medicine University of Miami
Magdi Elsallab
INNOVATION
12:40

Regulatory success parameters for translation of advanced therapies

13:00

Neworking Lunch

INNOVATION

Antonio Rodriguez
INNOVATION
14:00

Developing the First External Quality Assurance (EQA) Program for ATMPs

  • Design and development of the first External Quality Assurance (EQA) programme for ATMPs. Adapting the acquired experience from other fields of knowledge.
  • Promoting the harmonization of relevant Quality Control methods to guide manufacturers to develop safe and effective ATMPs.
  • State of development. Joining the programme and benefits to participants.
Maximilian Krippl
INNOVATION
14:40

Advanced Machine Learning in Bioprocess Development - How Hybrid Models can speed up bioprocess development

Sergey Piletsky
INNOVATION
15:00

Development of novel assays and sensors to support manufacturing and therapy

Sergey Piletsky, Professor, University of Leicester
Nada Alaaeddine
INNOVATION
15:20

Stem cells secretome and their efficiency in the treatment of soft tissue injury and skin rejuvenation

David Morrow
INNOVATION
15:40

Innovation in the regenerative medicine space

16:00

Networking refreshments

18:00

Close of conference

last published: 04/Jun/20 09:25